261 studies found for:    "Alkylating Agents" | updated in the last 30 days
Show Display Options
Rank Status Study
1 Recruiting A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia
Conditions: Chronic Lymphocytic Leukemia;   Leukemia
Interventions: Drug: Ibrutinib;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Rituximab
2 Recruiting Ph 3 Trial of Blinatumomab vs Investigator's Choice of Chemotherapy in Patients With Relapsed or Refractory ALL
Condition: Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Interventions: Drug: Blinatumomab;   Drug: Standard of Care Chemotherapy
3 Completed
Has Results
Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant
Conditions: Breast Cancer;   Chronic Myeloproliferative Disorders;   Gestational Trophoblastic Tumor;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Nausea and Vomiting;   Neuroblastoma;   Ovarian Cancer;   Testicular Germ Cell Tumor
Interventions: Drug: Aprepitant;   Drug: Cyclophosphamide;   Drug: Dexamethasone;   Drug: Granisetron hydrochloride
4 Completed Combination Chemotherapy and Autologous Peripheral Stem Cell Transplant in Treating Patients With Stage III, Stage IV, or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Conditions: Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Interventions: Biological: filgrastim;   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: melphalan;   Drug: paclitaxel;   Drug: topotecan hydrochloride;   Genetic: TdT-mediated dUTP nick end labeling assay;   Genetic: gene expression analysis;   Other: immunohistochemistry staining method;   Other: pharmacological study;   Procedure: peripheral blood stem cell transplantation
5 Recruiting Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers
Conditions: Hematologic Neoplasms;   Neural Tube Defects;   Myeloproliferative Disorders
Interventions: Drug: Rituximab;   Drug: Fludarabine;   Drug: Cyclosporine;   Drug: Etoposide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Cyclophosphamide;   Biological: T-Rapa cell DLI;   Procedure: T cell DLI;   Drug: Prednisone;   Procedure: Allogeneic HSCT;   Drug: Filgrastim
6 Active, not recruiting Treatment of Tumors of the Choroid Plexus Epithelium
Condition: Choroid Plexus Tumors
Interventions: Drug: Carboplatin;   Drug: Cyclophosphamide;   Drug: Etoposide;   Drug: Vincristine;   Radiation: Radiation Therapy
7 Recruiting A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve CLL or SLL
Conditions: Chronic Lymphocytic Leukemia;   Small-Cell Lymphoma
Interventions: Drug: Ibrutinib;   Drug: Obinutuzumab;   Drug: Chlorambucil
8 Recruiting Consolidation Therapy With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 in Patients With Chronic Lymphocytic Leukemia Following Upfront Chemotherapy With Pentostatin, Cyclophosphamide and Rituximab
Condition: Leukemia
Interventions: Drug: cyclophosphamide;   Biological: modified T cells
9 Recruiting Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts
Condition: Metastatic Melanoma
Interventions: Drug: Ipilimumab;   Procedure: Tumor Infiltrating Lymphocytes (TIL);   Drug: Administration of Lymphodepletion;   Drug: Cyclophosphamide as Part of Lymphodepletion;   Drug: Fludarabine as Part of Lymphodepletion;   Drug: High Dose IL-2;   Biological: Adoptive Cell Therapy with TIL
10 Terminated
Has Results
Maintenance Therapy: Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: Maintenance lenalidomide
11 Completed A Study of Avastin (Bevacizumab) and Irinotecan Versus Temozolomide Radiochemistry in Patients With Glioblastoma
Condition: Glioblastoma Multiforme
Interventions: Drug: bevacizumab [Avastin];   Drug: irinotecan;   Drug: temozolomide
12 Completed
Has Results
Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia
Conditions: Leukemia;   Lymphoma
Interventions: Biological: filgrastim;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: leucovorin calcium;   Drug: methotrexate;   Drug: prednisone;   Drug: vincristine sulfate;   Drug: Allopurinol
13 Recruiting Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy
Conditions: Hematopoietic/Lymphoid Cancer;   Nausea and Vomiting;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: Olanzapine;   Drug: Chemotherapy (cisplatin or cyclophosphamide and doxorubicin);   Drug: Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant);   Other: Placebo
14 Terminated
Has Results
In-Vivo Activated T-Cell Depletion to Prevent GVHD
Conditions: Acute Myelogenous Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myelogenous Leukemia;   Chronic Lymphocytic Leukemia;   Myelodysplasia;   Lymphoma, Non-Hodgkin's;   Mantle-Cell Lymphoma;   Hodgkin's Disease;   Multiple Myeloma;   Myelofibrosis
Interventions: Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Cyclosporine;   Drug: Mycophenolate mofetil;   Drug: Basiliximab
15 Active, not recruiting A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
Conditions: Melanoma;   Metastatic Melanoma;   Skin Cancer
Interventions: Drug: temozolomide;   Drug: ABT-888;   Drug: Placebo
16 Recruiting Romidepsin in Combination With CHOEP as First Line Treatment Before Hematopoietic Stem Cell Transplantation in Young Patients With Nodal Peripheral T-cell Lymphomas: a Phase I-II Study
Conditions: Peripheral T-cell Lymphomas (PTCL);   Peripheral T-cell Lymphomas Not Otherwise Specified (PTCL-NOS),;   Angioimmunoblastic T-cell Lymphoma (AITL);   ALK- Anaplastic Largecell Lymphoma (ALCL).
Interventions: Drug: Ro-CHOEP-21 (PHASE I);   Drug: Ro-CHOEP-21 (PHASE II)
17 Completed
Has Results
Post Marketing Surveillance: Newly Diagnosed Glioblastoma Multiforme Treated With Radiotherapy/Temozolomide and Adjuvant Temozolomide (Study P04739)
Condition: Glioblastoma
Interventions: Procedure: Primary surgical treatment;   Radiation: Radiotherapy;   Drug: Temozolomide
18 Active, not recruiting Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine
Conditions: HER2-positive Breast Cancer;   Recurrent Breast Cancer;   Recurrent Non-small Cell Lung Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Stage IV Breast Cancer;   Stage IV Non-small Cell Lung Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor
Interventions: Drug: ex vivo-expanded HER2-specific T cells;   Drug: cyclophosphamide;   Biological: denileukin diftitox;   Other: flow cytometry;   Other: immunoenzyme technique
19 Terminated
Has Results
Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps
Conditions: Hematologic Malignancies;   Acute Leukemia;   Myelodysplastic Syndromes (MDS) Other Than RA or RARS Subtypes.;   Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma;   Myeloma;   Chronic Myelogenous (or Myeloid) Leukemia (CML) Resistant to STI Therapy
Interventions: Drug: Fludarabine;   Drug: Thiotepa;   Radiation: Total Body Irradiation (TBI);   Biological: Donor Lymphocyte Infusion (DLI);   Drug: Melphalan;   Device: Hematopoietic stem cell transplantation (HSCT)
20 Recruiting Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma
Conditions: Stage II Childhood Anaplastic Large Cell Lymphoma;   Stage III Childhood Anaplastic Large Cell Lymphoma;   Stage IV Childhood Anaplastic Large Cell Lymphoma
Interventions: Drug: brentuximab vedotin;   Drug: crizotinib;   Drug: dexamethasone;   Drug: ifosfamide;   Drug: methotrexate;   Drug: cytarabine;   Drug: etoposide;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Other: laboratory biomarker analysis

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years